Annual Drug Patent Expirations for HETLIOZ+LQ
Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug.
Drug patent litigation for HETLIOZ LQ.
This drug has one hundred and eigthy-seven patent family members in twenty-four countries.
The generic ingredient in HETLIOZ LQ is tasimelteon. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
